AR068442A1 - Inhibidores de la epoxido hidrolasa soluble - Google Patents

Inhibidores de la epoxido hidrolasa soluble

Info

Publication number
AR068442A1
AR068442A1 ARP080103987A ARP080103987A AR068442A1 AR 068442 A1 AR068442 A1 AR 068442A1 AR P080103987 A ARP080103987 A AR P080103987A AR P080103987 A ARP080103987 A AR P080103987A AR 068442 A1 AR068442 A1 AR 068442A1
Authority
AR
Argentina
Prior art keywords
substituted
cycloalkyl
compositions
alkyl
group
Prior art date
Application number
ARP080103987A
Other languages
English (en)
Inventor
Sampath-Kumar Anandan
Richard D Gless Jr
Original Assignee
Arete Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arete Therapeutics Inc filed Critical Arete Therapeutics Inc
Publication of AR068442A1 publication Critical patent/AR068442A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/26—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos amida, tioamida, urea y tiourea y composiciones que inhiben la epoxido hidrolasa soluble (sEH), métodos de preparacion de dichos compuestos y composiciones y métodos para el tratamiento de pacientes con dichos compuestos y composiciones. Los compuestos, composiciones y métodos son de utilidad en el tratamiento de una variedad de enfermedades mediadas por sEH, incluyendo enfermedades hipertensivas, cardiovasculares, inflamatorias y aquellas relacionadas con la diabetes. Reivindicacion 1: Un compuesto caracterizado porque es de formula (1) o una: sal farmacéuticamente aceptable del mismo, en donde: L1 es un enlace covalente, -NH-, o -CR'Rö- donde R' y Rö son en forma independiente H o alquilo o R' y Rö juntos forman un anillo cicloalquilo C3-6; L2 es un enlace covalente o -CH2-; A es cicloalquilo sustituido o heterocíclico opcionalmente sustituido; X se selecciona entre el grupo que consiste en -O-, -C(=O)-, -S-, -SO-, -SO2-; y X no se conecta a L2; cada R1se selecciona en forma independiente entre el grupo que consiste en alquilo, alquilo sustituido, cicloalquilo, cicloalquilo sustituido, heterocicloalquilo, heterocicloalquilo sustituido, arilo, arilo sustituido, heteroarilo y heteroarilo sustituido, con la salvedad de que R1 no es piperidinilo sustituido; n es 0, 1, 2, 3 o 4; p es 0, 1, 2 o 3; Q es O o S; R se selecciona entre el grupo que consiste en: cicloalquilo C6-10, cicloalquilo C6-10 sustituido, y formula (2) en donde R4 y R8 son en forma independiente hidrogeno o fluor; R5, R6, y R7se seleccionan en forma independiente entre el grupo que consiste en hidrogeno, halo, alquilo, acilo, aciloxi, éster carboxílico, acilamino, aminocarbonilo, aminocarbonilamino, aminocarboniIoxi, aminosulfonilamino, (éster carboxílico)amino, aminosulfonilo, (sulfonilo sustituido)amino, haloalquilo, haloalcoxi, haloalquiltio, ciano; y alquilsulfonilo; con la salvedad de que cuando R es adamantilo, n es 0, y p es 2, X no es -C(=O)-.
ARP080103987A 2007-09-13 2008-09-12 Inhibidores de la epoxido hidrolasa soluble AR068442A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97215607P 2007-09-13 2007-09-13

Publications (1)

Publication Number Publication Date
AR068442A1 true AR068442A1 (es) 2009-11-18

Family

ID=40220787

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103987A AR068442A1 (es) 2007-09-13 2008-09-12 Inhibidores de la epoxido hidrolasa soluble

Country Status (4)

Country Link
US (1) US20090082423A1 (es)
AR (1) AR068442A1 (es)
TW (1) TW200930359A (es)
WO (1) WO2009035927A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3463470A1 (en) 2016-05-25 2019-04-10 Johann Wolfgang Goethe-Universität Frankfurt am Main Treatment and diagnosis of non-proliferative diabetic retinopathy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000563A1 (en) * 1987-07-17 1989-01-26 The Nutrasweet Company High potency sweetening agents
GB9504361D0 (en) * 1995-03-04 1995-04-26 Glaxo Spa Heterocyclic compounds
CA2584342C (en) * 2004-10-20 2013-04-30 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
TW200833663A (en) * 2006-12-21 2008-08-16 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
TW200930359A (en) 2009-07-16
US20090082423A1 (en) 2009-03-26
WO2009035927A2 (en) 2009-03-19
WO2009035927A3 (en) 2009-06-04
WO2009035927A8 (en) 2010-05-27

Similar Documents

Publication Publication Date Title
AR109958A1 (es) Lactamas bicíclicas de piridona y sus métodos de uso
AR083953A1 (es) Compuestos para tratar enfermedades neurodegenerativas
AR064389A1 (es) Derivados heterociclicos de nicotinamida utiles en el tratamiento de afecciones y enfermedades alergicas y respiratorias, y composiciones farmaceuticas que los contienen.
PE20110835A1 (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20210414A1 (es) Compuestos inhibidores de rip1 y metodos para preparar y usar los mismos
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
PE20040164A1 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas
AR063458A1 (es) Derivados de piridina inhibidores de 11beta hsd1
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
AR080314A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa
AR080865A1 (es) Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer.
AR047098A1 (es) Derivados de arilanilina como agonistas del receptor adrenergico beta2
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
ES2381683T3 (es) Compuestos de espiro-oxindol y sus usos como agentes terapéuticos
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
AR059338A1 (es) N-fenilbenzotriazolilo como inhibidores de c-kit
AR056103A1 (es) Compuestos de(piran-piperidinil)benzimidazol, composiciones farmaceuticas que los comprenden, proceso de preparacion y usos en el tratamiento de afecciones mediadas por agonistas del receptor muscarinico m1
AR045389A1 (es) Inhibidores del c-kit con estructura de pirazolil-amidil-benzoimidazolilo n-sustituido
AR074862A1 (es) Derivados de heterociclo biciclicos y sus metodos de uso
DOP2011000083A (es) Compuestos de amida utiles en terapia
RU2017101829A (ru) Пиразоловые соединения в качестве модуляторов fshr и пути их применения
AR059621A1 (es) Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
RU2018114077A (ru) Биарильное производное и содержащее его лекарственное средство

Legal Events

Date Code Title Description
FB Suspension of granting procedure